13
Oct
Oct
DEA has said that for now it is extending emergency telehealth policies set during the COVID-19 pandemic, enabling certain health care providers to have greater leeway in prescribing some controlled substances. The DEA decision affects buprenorphine for opioid addiction and stimulants such as amphetamine/dextroamphetamine (Adderall—Teva Pharmaceutics) used to treat ADHD. “We recognize the importance of […]